Omvoh
NDC 0002-8870, mirikizumab-mrkz, injection, solution, from Eli Lilly and Company.
- Product NDC
- 0002-8870
- Status
- Listed
- Labeler
- Eli Lilly and Company
- Dosage form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- BLA
- Application
- BLA761279
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/0002-8870 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- MIRIKIZUMAB100 mg/mL
Pharmacologic classes
Interleukin-23 Antagonist [EPC]; Interleukin-23 Antagonists [MoA]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 0002-8870-27 | 00002887027 | 2 SYRINGE in 1 CARTON (0002-8870-27) / 1 mL in 1 SYRINGE (0002-8870-01) |
Linked data
RxNorm, label and prices
Related lookups
FDA label sections
GET /v1/drugs/labels/472cbe04-263e-433d-9a0f-58c1b50b715aMedicare Part B payment limits (ASP)
GET /v1/drugs/asp?ndc=0002-8870
Use it
Look up 0002-8870 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/0002-8870 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 0002-8870. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.